Rockwell Automation IncRockwell Automation continued its participation in DataHow's bridge financing round, reinforcing its investment in the AI biopharma platform.

DataHow, a Swiss leader in AI-powered biopharmaceutical development solutions, has closed a bridge financing round extending its Series A, led by existing investor Momenta with continued participation from Rockwell Automation, HINA Bioventures, and Zürcher Kantonalbank. The new capital will accelerate three priorities for its DataHowLab platform: real-time connectivity, model-driven process control, and expansion into downstream processing. Since its Series A, DataHow has deployed its hybrid modelling technology across many of the industry's largest manufacturers, and this investment reflects confidence in that progress. CEO Dr. Alessandro Butté said customers are asking for real-time and downstream capabilities, and the funding lets the company respond directly. Momenta's Ken Forster highlighted the shift from automation to autonomy, while Rockwell's Matt Weaver emphasized the move from retrospective analysis to predictive, model-driven control.
Rockwell Automation IncRockwell Automation continued its participation in DataHow's bridge financing round, reinforcing its investment in the AI biopharma platform.
DataHow closed a bridge financing round extending its Series A to accelerate DataHowLab platform priorities.
Momenta led DataHow's bridge financing round as existing investor, deepening its investment in the platform's expansion.
HINA Bioventures continued its participation in DataHow's bridge financing round.